ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...
IRRI study highlights targeted investment in direct-seeded rice to enhance climate resilience and sustainability in Indian ...
Axon Neuroscience’s active tau immunotherapy, AADvac1, has been selected as the first tau-targeted therapy to enter a ...
ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease ...
All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage ...
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that ...
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.
A new study led by the University of Miami Miller School of Medicine's Kirill Martemyanov, Ph.D., and international ...
By simplifying the engineering process and expanding what can be built, the Golden Gate method greatly broadens the possibilities for scientists working to develop bacteriophages as tools to combat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results